New unconventional approaches to the development of antimicrobial drugs must target inhibition of infection stages leading to host colonisation or virulence itself, rather than bacterial viability. Amongst the most promising unconventional targets for the development of new antimicrobial drugs is bacterial adherence and biofilm formation as well as their control system, the quorum-sensing (QS) system, a mechanism of communication used to co-ordinate bacterial activities. Here we describe the evaluation of synthetic organic compounds as bacterial biofilm inhibitors against a panel of clinically relevant Grampositive and Gram-negative bacterial strains. This approach has successfully allowed the identification of five compounds (GEt, GHex, GOctad, G19 and C33) active not only against bacterial biofilms but also displaying potential to be used as antagonists and/or inhibitors of bacterial QS.
Introduction
The worldwide practice of indiscriminate and continuous use of antibiotics for the control and prophylaxis of bacterial pathogens has led to the development of bacterial resistance to most available antimicrobials [1] . Concurrently, the rapid increase in bacterial resistance to currently available antimicrobial drugs has led researchers to search for new sources of molecules active against bacterial pathogens, outlining a new generation of anti-infective drug development.
A promising approach for the development of a new generation of antimicrobial drugs has arisen from the studies of host-pathogen interactions, which prompted a shift of drug targets from bacterial survival to pathogenicity control. Examples of potential non-conventional targets for microbial control are molecules and receptors involved in bacterial adherence to biotic and abiotic surfaces as well as signal systems controlling bacterial group behaviour of populations organised in biofilms, such as quorum sensing (QS) [2] . In contrast to conventional antibiotics, antimicrobial drugs directed against such unconventional targets do not jeopardise bacterial survival, imposing a low selection pressure and thus avoiding the development of resistance [3] .
One of the most promising targets is systems controlling the early steps of bacterial adhesion, essential for the establishment of infection and colonisation in general, as well as the subsequent stage of biofilm formation [4] . Studies on bacterial resistance demonstrate that when organised in biofilms bacteria are able to survive antibiotic treatments at concentrations up to a thousand times higher than those used to kill their planktonic counterparts [5] . Conventional antibiotic therapies may eliminate the symptoms of an infection by eradicating planktonic bacteria arising from adhered populations, but are ineffective against those bacteria buried in biofilms, emphasising the importance of intervening in the adhesion process to avoid biofilm formation [6, 7] .
Experimental data have shown that biofilm formation, like the expression of many other virulence factors, responds to regulation dependent on population density [8] , e.g. QS; therefore, development of drugs interfering with QS appears to be a promising approach for the development of new antimicrobial drugs. Recent studies reported the identification of different classes of compounds capable of inhibiting or antagonising bacterial QS: synthetic halogenated furanones were identified as potent QS inhibitors to Pseudomonas aeruginosa (Fig. 1a and b) [7, 9] ; Smith et al. identified an antagonist of a P. aeruginosa autoinducer (AI) (Fig. 1c) [10] ; and, soon after, Geske et al. identified the most potent inhibitor reported to date against the QS of P. aeruginosa (Fig. 1d) [11] . More recently, esculetin (Fig. 1e) showed good activity as a QS inhibitor against Chromobacterium violaceum, Escherichia coli and P. aeruginosa [12] .
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.ijantimicag.2013. 07.006.
Here we describe the identification of new compounds capable of inhibiting biofilm formation of a panel of clinically relevant Gram-positive and Gram-negative bacterial pathogens. These compounds, which include alkyl-esters of gallic acid, (E)-N -benzylidene-benzohydrazides, 1,3,4-oxadiazoles and (E)-chalcones, were chosen for the present study on the basis of their similarity to some known QS inhibitors (Fig. 1) [7, [9] [10] [11] [12] . Quantification of their activities against biofilm formation, indicative of their potential use in the control of biofilm-related infections, allowed structure-function analysis that will guide future studies in the search for new compounds to be used for biofilm control. Analysis of cytotoxicity against human cells allowed the identification of molecules potentially suitable for the development of new antibiofilm drugs for therapeutic purposes.
Materials and methods

Bacterial strains
Standard reference strains Enterococcus faecalis ATCC 19433, P. aeruginosa ATCC 27853, Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 35547 and Streptococcus mutans ATCC 25175 were used in this study. Isolates were kept in trypticase soy broth (TSB) supplemented with 20% (v/v) glycerol at −20 • C and were routinely cultivated in TSB. Conditions for the best biofilm production were established for each strain (data not shown) and are mentioned when necessary.
Synthesis and purification of the compounds
Reagents were obtained commercially from Sigma-Aldrich (St. Louis, MO) and solvents were from Vetec (Duque de Caxias, Brazil). Exceptions were 3,4,5-trimethoxybenzohydrazide, 2,4,5-trimethoxyacetophenone and 3-methoxy-4-(phenylmethoxy)-benzaldehyde, prepared as previously described [13] [14] [15] , with yields of 80%, 81% and 88%, respectively.
All alkyl-esters of gallic acid were synthesised and characterised as previously described [16] . Gallic acid (5 mmol) and the corresponding alcohol (15 mmol) were mixed. For compounds GMet, GEt, GProp, GBut and GHex, the mixture was dissolved in toluene (70 mL) and concentrated sulphuric acid (0.4 mL), heated for 8-12 h in reflux using a Dean-Stark apparatus, and the solvent was removed under reduced pressure. For compounds GOct and GOctad, the mixture was dissolved in dioxane (10 mL) and ptoluenesulfonic acid (0.3 mL) and heated for 2-4 h in bath oil under vacuum. All products were purified by column chromatography.
The (E)-N -benzylidene-benzohydrazides were synthesised as previously described [17, 18] by condensation of the benzohydrazide (2 mmol) or 3,4,5-trimethoxy-benzohydrazide (2 mmol) with the appropriate aldehyde (2 mmol) in methanol (15 mL) and refluxing for 2 h. After cooling, the crude product was collected by filtration, washed and recrystallised from hot ethanol to give white solids. The compounds G1, G8, G23 and G24 have been previously described [14] and compounds G7, G19 and F41 were recently patented by our group [19] . The 1,3,4-oxadiazoles were prepared by cyclisation of the previously obtained (E)-N -benzylidene-benzohydrazides with acetic anhydride under reflux for 3 h as described previously [20] . After cooling, the crude product was collected by filtration, washed and recrystallised from acetone/water to give white solids. The compounds Y18, Z43 and Z47 have been previously described [21] and compounds Z5 and Z8 were recently patented by our group [19] .
The (E)-chalcones were prepared by aldol condensation using methanol as solvent under basic conditions (KOH 50%, w/v) at room temperature for 24 h. Distilled water and 10% hydrochloric acid were added to the reaction for total precipitation of the compounds, which were then obtained by vacuum filtration and later recrystallised in dichloromethane and hexane. All structures (C1, C6, C7, C24, C28, C33, C37, L15, L48, L50, J4, J61, J62, Lou5, R58 and R61) were previously described by our group [21] [22] [23] .
Bacterial growth and biofilm inhibition assays
Biofilm production and quantification assays were performed by colorimetric assay as described previously [24] . No antibiotics were added at any point during these assays. To assay for biofilm inhibition, bacterial strains were grown statically for 20 h at 37 • C in TSB. Polystyrene 96-well microtitre plates were then inoculated with 100 L/well of bacterial suspension previously diluted to 5 × 10 8 CFU/mL in TSB supplemented with 4% sucrose (w/v) and 3.5% (v/v) dimethyl sulphoxide (DMSO). Then, 100 L of the compound to be tested for antibiofilm activity, prepared in TSB supplemented with 4% sucrose (w/v) and 3.5% (v/v) DMSO, was added to the first well. After homogenisation by pipetting up and down the 200 L content of the well, 100 L of this mixture was transferred to the next well and the procedure was repeated until a final concentration of 0.2 g/mL was reached, and the final volume of each well was 100 L. Microtitre plates were incubated for 20 h at 37 • C in a humidified chamber and bacterial growth was quantified by absorbance at 630 nm to assess eventual growth inhibition. Bacterial suspensions were discarded and biofilm was stained with a 0.1% (w/v) crystal violet solution for quantification. After solubilisation of crystal violet in 1% sodium dodecyl sulphate (SDS), biofilm was quantified by measuring the absorbance at 595 nm. For S. mutans assays, incubation was performed in microaerophilic conditions. Eventual growth inhibition was accessed for each compound by reading the optical density at 600 nm before biofilm quantification. Growth inhibition, when identified, was considered as an indication of potential conventional antibacterial properties of the chemical compounds, and those compounds were selected for future investigation.
Cell culture and selectivity assays
Selectivity towards bacteria of molecules positive for biofilm inhibition was evaluated using the human glioma cell line A172 by the MTT (thialyl blue tetrazolium bromide) colorimetric assay as previously described [25] . Briefly, A172 cells were cultured in Dulbecco's Modified Eagle Medium: nutrient mixture F-12 supplemented with 10% foetal bovine serum in 25 cm 2 culture flasks at 37 • C in a humidified atmosphere of 5% CO 2 . Cells were plated in 96-well plates and were subsequently exposed for 24 h to the compounds for cytotoxicity assays. Cell viability was quantified by MTT colorimetric assay. Absorbance was measured at 540 nm and results were expressed as percentage viability of the control samples.
Statistical analysis
The significance of differences was evaluated by means of oneway analysis of variance (ANOVA) with the Newman-Keuls post test using GraphPad InStat software (GraphPad Software Inc., La Jolla, CA). The level of significance was set at P < 0.05 in all cases.
Results
Synthesis of the compounds
All tested compounds (Table 1) were previously prepared by our research group, with yields ranging between 21% and 99% [16, 19, [21] [22] [23] .
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.ijantimicag.2013. 07.006. Table 2 shows the results of biofilm inhibition for each assayed compound as well as the concentrations at which these inhibitions levels were observed (indicated in brackets). All experiments were performed in triplicate, with the mean and standard deviation shown in Table 2 .
Quantification of biofilm inhibition activities
Cytotoxicity of compounds active against biofilm
Cytotoxicity assays against human glioma A172 cells were performed with compounds at the concentration where they displayed maximum antibiofilm activity (indicated in brackets in Table 2 ). Results obtained for cytotoxicity are summarised in Table 3 .
Discussion
The criteria for determining the structures of synthesised and tested compounds (Table 1) for biofilm inhibition followed the principle of molecular similarity, favouring either molecular structures similar to QS inhibitors described in the literature (Fig. 1 ) [7, [9] [10] [11] [12] 26] or structures derived from those with reported antibacterial activities [21] . Biofilm inhibition rates were calculated using the mean biofilm production obtained in each experiment performed in triplicate (Table 2 ). Inhibition levels >50% were generally visible to the naked eye.
The results of biofilm inhibition assays for alkyl-esters of gallic acid (Table 2) showed that, in general, Gram-positive bacteria were the most susceptible to this class of compounds. Regarding species specificity, amongst the Gram-positives, E. faecalis and S. aureus showed sensitivity to most of the alkyl-esters of gallic acid tested. Methyl gallate (GMet) was the only derivative displaying activity against biofilms of all evaluated bacterial strains. Increases in compound hydrophobicity, as result of increases in the size of their carbon side chains, did not appear to interfere with their activities against biofilms of E. faecalis and S. aureus, suggesting that the three hydroxyl groups at the phenyl ring correspond to the important portion of the molecule for activity (pharmacophore). This information is supported by Ni et al. who evaluated pyrogallol derivatives, compounds that also have the trihydroxyphenyl ring, and showed that they confer QS antagonist activity in Vibrio harveyi [27] . However, increases in the hydrophobicity of alkyl-esters of gallic acid did affect their activities specifically against biofilm of S. mutans, as the 91% inhibition activity displayed by methyl gallate (GMet) decreased to <10% with the increasing of carbon side chains. The results described by Ni et al. [27] with pyrogallol derivatives on the activity of AI-2 suggest that the mechanism of biofilm inhibition of alkyl-esters of gallic acid occurs through an antagonistic effect on AI-2 or its receptor, LuxP [28] . Based on the concept of molecular mimicry, it is possible that other compounds capable of complexing to boric acid could potentially bind to LuxP, acting as QS inhibitors, as in the case of alkyl-esters of gallic acid, and possibly some (E)-N -benzylidene-benzohydrazides assayed. Table 2 also summarises the results of biofilm inhibition obtained for (E)-N -benzylidene-benzohydrazides. Compounds without substituents at the phenyl A ring were more active against most of the Gram-positive species tested (E. faecalis, S. aureus and S. epidermidis). Interestingly, simultaneous addition of trimethoxy substituents at positions 3, 4 and 5 in the A ring (F41) shifts this biofilm inhibitory effect towards S. mutans and P. aeruginosa, with activity against the other bacterial strains being completely lost. The different effects of these N -benzylidene-benzohydrazides on biofilms of Gram-positive species compared with P. aeruginosa (Gram-negative) allow speculation about its mechanism of inhibition. Both in Gram-positive and Gram-negative bacteria, biofilm is primarily regulated by QS. However, whilst Gram-negative bacteria generally use acylated homoserine lactone derivatives as autoinducers (AI-1), Gram-positive bacteria typically respond to modified peptides (AIP). Results obtained here with (E)-N -benzylidene-benzohydrazides suggest that these compounds exert an effect on biofilm through antagonism of the QS pathway mediated by AIPs, showing weak or no antagonist effect on Gram-negative AI-1-mediated QS [8] . In the case of compounds G7, G19 and F41, which showed activity both on Gram-positive and Gram-negative biofilms, the mechanism of inhibition of these (E)-N -benzylidene-benzohydrazides might occur through the universal system of QS, possibly by antagonising the action of AI-2, similar to the alkyl-esters of gallic acid. The best inhibitory activities were displayed by compound G23 (which has a hydroxyl group in position 2 and a bromine atom at position 5 of the B ring), compound G7 (with a hydroxyl group in position 4 and a nitro group in position 3 of the B ring) and compound G19 (with a bromine atom in position 4 of the B ring). Interestingly, when the B ring is a 2-chloroquinoline group (G1) the compound shows moderate activity, and it becomes inactive when the B ring is replaced by the 4-CF 3 -phenyl group (a hydrophobic group, strong electronwithdrawing) (G24) or is replaced by the 3-pyridine group (G8). These observations suggest that the balance between hydrophobicity (bromine or nitro, bulky and electron-withdrawing groups) and hydrophilicity (hydroxyl, electron donor group) in the B ring might be an important factor for the activity of (E)-N -benzylidenebenzohydrazides (G7 and G23), when the ring A is the phenyl group without substituents. It is interesting to note that some furanones, important QS inhibitors described in the literature, also have a bromine atom whose presence is important for antibiofilm activity (Fig. 1) [7, 9, 11, 28] .
Compared with (E)-N -benzylidene-benzohydrazides, the 1,3,4-oxadiazoles are more rigid structures owing to the central heterocyclic ring. This rigidity apparently confers loss of activity of the compounds. The most sensitive species to 1,3,4-oxadiazoles was S. aureus ( Table 2) . Compounds of this class with methoxyl groups (Z8, Z43 and Z47) or without substituents at the A ring (Y18) were not active against biofilm. Only compound Z5 showed significant biofilm inhibitory activity without interfering with bacterial growth. Similar to that observed for (E)-N -benzylidenebenzohydrazides, apparently the ring B substituted by a bromine atom (at position 5) and a hydroxyl group (at position 4), followed in this case by a methoxyl group in position 3, favoured the activity against biofilm (Z5). Again, the balance between hydrophobicity (bromine, a electron-withdrawing and bulky group) and hydrophilicity (hydroxyl and methoxyl, electron donor groups) in the B ring appears to be important for activity (Z5), as well as the presence of methoxyl groups at positions 3, 4 and 5 in the A ring. Compounds with chlorine atoms (electron-withdrawing substituents) in the B ring (Z43 and Z47), even at position 3, or the 1-naphthyl group (hydrophobic) as B ring (Z8), exhibited weak activity against biofilm, although interfering with bacterial growth (Z43 and Z47). These findings suggest that the presence of only electron-withdrawing groups at the B ring (Z43 and Z47) or a hydrophobic B ring (Z8) does not favour 1,3,4-oxadiazole activity against biofilms.
Results of biofilm inhibition obtained for (E)-chalcones (Table  2) showed that these compounds exhibit greater biofilm activity against Gram-positive species, although C7 was capable of inhibiting P. aeruginosa biofilm at a 56% rate. Moreover, this compound, which has as substituent the imidazole group at position 4 of the A ring, and the 2-naphthyl group as B ring, was active against biofilms of all strains tested, showing excellent rates of inhibition, especially against S. aureus, S. epidermidis and P. aeruginosa, being less effective against E. faecalis. This compound exhibits a strong electronic conjugation, which seems to be related to its antibiofilm activity. However, when the B ring is substituted by the 3-methoxy-4-(phenylmethoxy)-phenyl group (R58), the activity is reduced. These observations appear to indicate that the A ring with substituents in conjugation with the carbonyl group, and the presence of a planar and hydrophobic/lipophilic B ring (2-naphthyl), appears to be crucial for antibiofilm activity of the (E)-chalcones. The (E)-chalcones with methoxyl groups at positions 2, 4 and 5 of the A ring and the 2-naphthyl (J4) or 2-chloroquinoline (J61 and J62) group as B ring did not show antibiofilm activity. However, compound L48, which has the 3,4-methylenedioxy-phenyl group as A ring, and also the 2-chloroquinoline group as B ring, showed excellent activity. Amongst the (E)-chalcones L15 and L50, also with the 3,4-methylenedioxy-phenyl group as A ring, the highest biofilm inhibitory activity was displayed by the compound with the 2-naphthyl group as B ring (L15). These findings demonstrate once again the importance of the presence of the hydrophobic/lipophilic B ring (quinoline or 2-naphthyl groups) associated with the 3,4-methylenedioxy group as the substituent of the A ring for the good activity of this class of compounds. In general, (E)-chalcones with three methoxyl groups at the A ring showed moderate (C24 and J4) or no activity (J61 and J62) against bacterial biofilm, even when the B ring is the 2-naphthyl group (C24 and J4), indicating that steric effects due to these substituents might be reducing the antibiofilm activity. However, when the B ring is the 2-naphthyl group, the presence of one (C28) or two (C1, C6, C33 and C37) methoxyl groups at the A ring favours the antibiofilm activity, especially when these are in position 3 (C1, C6 and C33). The (E)-chalcone C37, with methoxyl groups in positions 2 and 5 of the A ring, showed moderate activity for S. aureus and S. mutans biofilms. When the B ring was replaced by a nitrogenated heterocycle substituted with a 3-CF 3 -phenyl group, the activity against S. mutans is drastically reduced (Lou5). Similar results were observed for the (E)-N -benzylidenebenzohydrazides, where compounds with the CF 3 substituent at the B ring (G24) did not show activity against any of the tested strains. When the A ring is the 2-chlorotiophen group (non-polar) and the B ring is the 3-methoxy-4-(phenylmethoxy)-phenyl group, the (E)-chalcone also showed low activity (R61). Taken together, these observations allow us to conclude that the activity of the (E)-chalcones against biofilm is dependent on steric and electronic factors, with the following structural characteristics appearing as important for this activity: (i) A ring with substituents in conjunction with the carbonyl group, such as 4-phenyl-imidazole; (ii) substituents able to make hydrogen bonds in the A ring, such as 3,4-methylenedioxy group or one or two methoxyl groups; and (iii) hydrophobic/polar B ring. Conversely, the results indicate that either the presence of three methoxyl groups in the A ring, or a non-polar A ring, did not favour the antibiofilm activity of the (E)-chalcones.
Compounds showing biofilm inhibition levels ≥50% were selected for further evaluation of their selectivity towards bacteria using human glioma A172 cells. Selectivity assays were performed with compounds at the concentration where they displayed maximum antibiofilm activity (indicated in brackets in Table 2 ). The results obtained are summarised in Table 3 and demonstrate that amongst the alkyl-esters of gallic acid tested, compounds GEt, GHex and GOctad showed no cytotoxicity against human glioma A172 cells, thus suggesting that their activity is selectively directed against bacteria. Amongst these compounds, GOctad was the one showing the best biofilm inhibitory activity (75% inhibition against S. aureus) ( Table 2 ). Compounds GMet and GOct, although showing the best biofilm inhibitory activities amongst the alkyl-esters of gallic acid tested, were toxic against human cells, precluding their potential therapeutic use in biofilm control. In the (E)-Nbenzylidene-benzohydrazide group, results indicate compound G19 (61% biofilm inhibition against S. aureus) as the best candidate for use in biofilm therapeutics. Compound G23, although showing the best biofilm inhibitory activity amongst the (E)-N -benzylidenebenzohydrazides, showed high cytotoxicity levels against human cells. Compound Z5 was the only 1,3,4-oxadiazol showing significant biofilm inhibition activity and it also displayed a high level of cytotoxicity against human cells, excluding this group of compounds from potential therapeutic use for biofilm control. Amongst the (E)-chalcones tested, compound C33, which inhibited S. mutans biofilm at a rate of 70%, was the least toxic against human glioma A172 cells, followed by compound L48, active against biofilms of E. faecalis (89% inhibition), S. aureus (66% inhibition) and S. epidermidis (85% inhibition). These results indicate that compounds GEt, GHex, GOctad, G19 and C33 are selective for bacterial biofilms and do not show toxicity against human glioma A172 cells. Further studies are needed to access the overall toxicity of these compounds, which will be conducted and presented in a future work, with in vivo assessments.
The results obtained here revealed that the steric and electronic characteristics favouring the biofilm inhibitory activity of (E)-chalcones are different from those that favour the activity of (E)-N -benzylidene-benzohydrazides, 1,3,4-oxadiazoles and alkylesters of gallic acid. To (E)-chalcones, the presence of substituents in conjunction with the carbonyl group or the ability to make hydrogen bonds in the A ring, as well as a hydrophobic/polar B ring, is important. To (E)-N -benzylidene-benzohydrazides and 1,3,4-oxadiazoles, the balance between hydrophobicity and hydrophilicity in the B ring appears to be important for antibiofilm activity, although the oxadiazoles are more rigid structures compared with their precursors (E)-N -benzylidene-benzohydrazides and this rigidity apparently confers loss of activity of this class of compounds. Finally, for the alkyl-esters of gallic acid, results suggest that the portion of the molecule important for its activity comprises the three hydroxyls groups at the phenyl ring, and that hydrophobicity apparently does not appear to induce a change in activity.
It is important to note that toxicity towards human glioma A172 cells of compounds with significant biofilm inhibition activity identified here, although being a drawback for their use in therapeutics, does not preclude their potential development for the functionalisation of materials used for other purposes, such as biofouling control in closed systems. Evaluation of such potential for some compounds identified here is currently under study, and studies on the mechanisms of biofilm inhibition are underway to evaluate the potential use of the more active and selective compounds (GEt, GHex, GOctad, G19 and C33) for biofilm control in vivo. Furthermore, ongoing studies in our laboratory to consolidate the potential use of these compounds, shown here as active against biofilm formation, include tests against a range of bacterial isolates, as well as clinical strains, chosen in accordance with their foreseen applications.
